SCHEMBL5281575

SCHEMBL5281575

[CH2]N(c1ccccc1)S(=O)(=O)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APOBEC3G Q9HC16 1/20 0.52
ALDH1A1 P00352 2/20 0.50
PKM P14618 1/20 0.50
ESR1 P03372 3/20 0.47
CA12 O43570 2/20 0.46
CA9 Q16790 2/20 0.46
KMT2A Q03164 1/20 0.46
HTR6 P50406 1/20 0.44
LMNA P02545 1/20 0.43
TDP1 Q9NUW8 2/20 0.41
HSD11B1 P28845 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA3 P07451 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
PLA2G7 Q13093 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11576079 0.76 APOBEC3G (0.56) APOBEC3GALDH1A1PKMESR1CA12
SCHEMBL812682 0.76 PKM (0.79) APOBEC3GALDH1A1PKMESR1CA12
SCHEMBL2371758 0.74 APOBEC3G (0.54) APOBEC3GALDH1A1PKMESR1CA12
SCHEMBL9453750 0.74 TSHR (0.42) ALDH1A1PKMESR1CA12CA9
SCHEMBL4980683 0.74 NR3C2 (0.41) ALDH1A1PKMESR1CA12CA9
SCHEMBL2372572 0.74 APOBEC3G (0.54) APOBEC3GALDH1A1CA12CA9KMT2A
SCHEMBL6432835 0.73 APOBEC3G (0.52) APOBEC3GALDH1A1PKMESR1CA12
SCHEMBL22257152 0.73 APOBEC3G (0.52) APOBEC3GALDH1A1PKMESR1CA12
SCHEMBL10640658 0.73 APOBEC3G (0.52) APOBEC3GALDH1A1PKMESR1CA12
SCHEMBL141091 0.73 APOBEC3G (0.64) APOBEC3GALDH1A1PKMESR1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO claimed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US claimed
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 APOBEC3G 4448/4885ALDH1A1 2972/4885PKM 4619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.